Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 122

1.

Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer.

Ramalingam SS, Harvey RD, Saba N, Owonikoko TK, Kauh J, Shin DM, Sun SY, Strychor S, Tighiouart M, Egorin MJ, Fu H, Khuri FR.

Cancer. 2010 Aug 15;116(16):3903-9. doi: 10.1002/cncr.25264.

PMID:
20564143
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

[Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].

Li JL, Zhang XR, Liu JW, Chen ZY, Lin YC, Wang YD, Chen Q, Nan KJ, Song SP, Han FC, Zhu YZ, Li LY, Zheng YH, Chu DT.

Zhonghua Zhong Liu Za Zhi. 2006 Apr;28(4):309-12. Chinese.

PMID:
16875636
[PubMed - indexed for MEDLINE]
3.

A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer.

Moulder S, Gladish G, Ensor J, Gonzalez-Angulo AM, Cristofanilli M, Murray JL, Booser D, Giordano SH, Brewster A, Moore J, Rivera E, Hortobagyi GN, Tran HT.

Cancer. 2012 May 1;118(9):2378-84. doi: 10.1002/cncr.26571. Epub 2011 Oct 17.

PMID:
22006179
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer.

Argiris A, Kut V, Luong L, Avram MJ.

Invest New Drugs. 2006 May;24(3):203-12.

PMID:
16096702
[PubMed - indexed for MEDLINE]
5.

Phase I study of second-line chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer.

Oka M, Fukuda M, Nagashima S, Fukuda M, Kinoshita A, Soda H, Doi S, Narasaki F, Suenaga M, Takatani H, Nakamura Y, Kawabata S, Tsurutani J, Kanda T, Kohno S.

Cancer Chemother Pharmacol. 2001 Dec;48(6):446-50.

PMID:
11800024
[PubMed - indexed for MEDLINE]
6.

Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer.

Millward MJ, Zalcberg J, Bishop JF, Webster LK, Zimet A, Rischin D, Toner GC, Laird J, Cosolo W, Urch M, Bruno R, Loret C, James R, Blanc C.

J Clin Oncol. 1997 Feb;15(2):750-8.

PMID:
9053501
[PubMed - indexed for MEDLINE]
7.

A phase I dose escalation study of weekly docetaxel and carboplatin in elderly patients with nonsmall cell lung cancer.

Kaira K, Tsuchiya S, Sunaga N, Yanagitani N, Watanabe S, Imai H, Hisada T, Ishizuka T, Saito R, Mori M.

Am J Clin Oncol. 2007 Feb;30(1):51-6.

PMID:
17278895
[PubMed - indexed for MEDLINE]
8.

Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.

Papadimitrakopoulou VA, Soria JC, Jappe A, Jehl V, Klimovsky J, Johnson BE.

J Thorac Oncol. 2012 Oct;7(10):1594-601. doi: 10.1097/JTO.0b013e3182614835.

PMID:
22968184
[PubMed - indexed for MEDLINE]
9.

Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies.

Schneider BJ, Kalemkerian GP, Bradley D, Smith DC, Egorin MJ, Daignault S, Dunn R, Hussain M.

Invest New Drugs. 2012 Feb;30(1):249-57. doi: 10.1007/s10637-010-9503-6. Epub 2010 Aug 5.

PMID:
20686817
[PubMed - indexed for MEDLINE]
10.

Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer.

Ramalingam SS, Owonikoko TK, Behera M, Subramanian J, Saba NF, Kono SA, Gal AA, Sica G, Harvey RD, Chen Z, Klass CM, Shin DM, Fu H, Sun SY, Govindan R, Khuri FR.

J Thorac Oncol. 2013 Mar;8(3):369-72. doi: 10.1097/JTO.0b013e318282709c.

PMID:
23407561
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.

Kakolyris S, Souglakos J, Agelaki S, Kourousis CH, Mavroudis D, Sarra E, Malliotakis P, Georgoulias V.

Lung Cancer. 2000 Dec;30(3):193-8.

PMID:
11137204
[PubMed - indexed for MEDLINE]
12.

A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer.

Kosmas C, Tsavaris NB, Makatsoris T, Onyenadum A, Vadiaka M, Stavroyianni N, Sepsas E, Dimitropoulos D, Rokana S, Kalofonos HP.

Int J Cancer. 2002 Mar 1;98(1):141-7.

PMID:
11857398
[PubMed - indexed for MEDLINE]
13.

Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model.

Vansteenkiste J, Solomon B, Boyer M, Wolf J, Miller N, Di Scala L, Pylvaenaeinen I, Petrovic K, Dimitrijevic S, Anrys B, Laack E.

J Thorac Oncol. 2011 Dec;6(12):2120-9. doi: 10.1097/JTO.0b013e3182307ede.

PMID:
21900840
[PubMed - indexed for MEDLINE]
14.

A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131.

Gelmon KA, Stewart D, Chi KN, Chia S, Cripps C, Huan S, Janke S, Ayers D, Fry D, Shabbits JA, Walsh W, McIntosh L, Seymour LK.

Ann Oncol. 2004 Jul;15(7):1115-22.

PMID:
15205207
[PubMed - indexed for MEDLINE]
Free Article
15.

Docetaxel and cisplatin as second-line chemotherapy for advanced non-small cell lung cancer.

Hamada H, Irifune K, Ito R, Sakai K, Kadowaki T, Katayama H, Abe M, Shiode M, Nishimura K, Higaki J.

Gan To Kagaku Ryoho. 2007 Aug;34(8):1235-9.

PMID:
17687204
[PubMed - indexed for MEDLINE]
16.

A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer.

Kouroussis C, Agelaki S, Mavroudis D, Kakolyris S, Androulakis N, Kalbakis K, Souglakos J, Mallas K, Bozionelou V, Pallis A, Adamtziki H, Georgoulias V.

Anticancer Res. 2003 Jan-Feb;23(1B):785-91.

PMID:
12680184
[PubMed - indexed for MEDLINE]
17.

Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.

Milton DT, Riely GJ, Azzoli CG, Gomez JE, Heelan RT, Kris MG, Krug LM, Pao W, Pizzo B, Rizvi NA, Miller VA.

Cancer. 2007 Aug 1;110(3):599-605.

PMID:
17577220
[PubMed - indexed for MEDLINE]
Free Article
18.

Phase I/II trial of docetaxel and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy.

Leu KM, Kim KM, Larson M, Larson M, Schiller JH.

Lung Cancer. 2001 Oct;34(1):105-13.

PMID:
11557120
[PubMed - indexed for MEDLINE]
19.

Phase II study of docetaxel and carboplatin in elderly patients with advanced non-small cell lung cancer.

Yoshimura N, Kudoh S, Kimura T, Mitsuoka S, Kyoh S, Tochino Y, Asai K, Kodama T, Ichimaru Y, Yana T, Hirata K.

J Thorac Oncol. 2009 Mar;4(3):371-5. doi: 10.1097/JTO.0b013e31819846e4.

PMID:
19155998
[PubMed - indexed for MEDLINE]
20.

A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma.

Han JY, Lee DH, Kim HY, Hong EK, Yoon SM, Chun JH, Lee HG, Lee SY, Shin EH, Lee JS.

Cancer. 2003 Nov 1;98(9):1918-24.

PMID:
14584075
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk